FDA Deals Another Blow to AstraZeneca’s Blood Drug


The U.S. Food and Drug Administration gave AstraZeneca’s New Drug Application for ZS-9 (sodium zirconium cyclosiliate) a Complete Response Letter (CRL) — again. The drug was being developed for hyperkalemia by ZS Pharma, a wholly owned subsidiary of AstraZeneca.
Source link